Catherine Thieblemont, MD, PhD

home / authors / catherine-thieblemont-md-phd

Articles

Updates in Splenic and Nodal Marginal Zone Lymphoma

December 19th 2017

This video reviews updates on the treatment and biology of splenic and nodal marginal zone lymphoma.

Splenic Marginal Zone Lymphoma: Current Knowledge and Future Directions

Catherine Thieblemont, MD, PhD;Frederic Davi, PhD;Maria-elena Noguera, MD;Josette Brière, MD, PhD;Francesco Bertoni, MD;Emanuele Zucca, MD;Alexandra Traverse-glehen, MD, PhD;Pascale Felman, MD;Françoise Berger, MD, PhD;Gilles Salles, MD, PhD;Bertrand Coiffier, MD, PhD

February 15th 2012

In this article, we review the current knowledge on the biological findings, clinical features, and therapeutic approaches for splenic marginal zone lymphoma.

Nodal Marginal Zone B-Cell Lymphoma: A Diagnostic and Therapeutic Dilemma

Alexandra Traverse-glehen, MD, PhD;Francesco Bertoni, MD;Catherine Thieblemont, MD, PhD;Emanuele Zucca, MD;Bertrand Coiffier, MD, PhD;Françoise Berger, MD, PhD;Gilles Salles, MD, PhD

January 17th 2012

The aim of this review is twofold: to summarize descriptions of the clinical presentation provided in published series in order to help clinicians recognize and treat patients, and to discuss diagnostic difficulties faced by hematopathologists when dealing with these lesions and others in the differential diagnosis that must be distinguished from one another.

MALT Lymphomas: Pathogenesis Can Drive Treatment

Francesco Bertoni, MD;Bertrand Coiffier, MD, PhD;Gilles Salles, MD, PhD;Anastasios Stathis, MD;Alexandra Traverse-glehen, MD, PhD;Catherine Thieblemont, MD, PhD;Emanuele Zucca, MD

November 15th 2011

Marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent B-cell non-Hodgkin lymphoma arising from the lymphoid tissue at extranodal sites.

Activity of Rituximab in Extranodal Marginal Zone Lymphomas (MALT Type)

A. Conconi;Catherine Thieblemont, MD, PhD;G. Martinelli;A. J. M. Ferreri;L. Devizzi;F. Peccatori;M. Ponzoni;V. Filipazzi;P. Y. Dietrich;M. A. Gianni;Franco Cavalli, MD, FRCP;Emanuele Zucca, MD

March 1st 2002

This phase II study aimed to evaluate the tolerability and activity of the monoclonal anti-CD20 antibody rituximab (Rituxan) in patients with either untreated or relapsed biopsy-proven extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) type, with measurable or evaluable disease.